{"id":"W2147486721","doi":"10.1002/cncr.27745","title":"Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Bortezomib; Bevacizumab; Multiple myeloma; Clinical endpoint; Internal medicine; Hazard ratio; Refractory (planetary science); Adverse effect; Placebo; Gastroenterology; Proteasome inhibitor; Phases of clinical research; Progressive disease; Oncology; Surgery; Randomized controlled trial; Confidence interval; Clinical trial; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005704871,0.0002697805,0.001056032,0.0002083344,0.00005787351,0.00001222984,0.00009366301,0.00013088,0.0002693414],"category_scores_gemma":[0.002144587,0.0001881107,0.0001034521,0.0002675,0.0001543992,0.0001551363,0.00007607601,0.0002942234,0.0000125831],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002931405,"about_ca_system_score_gemma":0.0002393236,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008213732,"about_ca_topic_score_gemma":0.003009572,"domain_scores_codex":[0.9975539,0.0003026483,0.0007065321,0.0004393474,0.0004782422,0.0005193708],"domain_scores_gemma":[0.9971728,0.001520972,0.0002407278,0.0005334853,0.0001154845,0.0004164707],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9062298,0.00468025,0.04396568,0.00004593514,0.0009561162,0.0002374259,0.004887119,0.000002151549,0.001762111,0.000002342076,0.0004962339,0.03673486],"study_design_scores_gemma":[0.8768673,0.001743841,0.1161117,0.0001626128,0.0003901986,0.000004185332,0.001326615,0.0007168757,0.001451998,0.000003705531,0.001038657,0.0001823553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927371,0.003439527,0.000003361087,0.0001054968,0.000357782,0.002451484,0.0003478834,0.00003543713,0.0005219259],"genre_scores_gemma":[0.9976214,0.0007233453,0.0002458061,0.00003493058,0.0002239985,0.0004705914,0.0001347491,0.00003822599,0.0005069306],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07214599,"threshold_uncertainty_score":0.9983907,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06845420894354572,"score_gpt":0.3886860045544843,"score_spread":0.3202317956109386,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}